ShanghaiApril 24, 2026 /PRNewswire/ — For lung cancer patients, racing against time is the norm. When standard treatment options fail, or when faced with challenging rare mutations, the urgent question often becomes: “Are there cutting-edge, more precise drugs available?”
The answer is: Yes, and at Shanghai Delta Hospital, the clinical accessibility of these cutting-edge drugs is accelerating the hope of ‘having effective medication’ into reality.
Leveraging a robust drug introduction capability and a multidisciplinary diagnosis and treatment platform, the Oncology Department at Shanghai Delta Hospital has fully introduced and clinically applied multiple innovative lung cancer drugs representing international frontiers. Covering areas such as targeted therapy, immunotherapy, and ADC (Antibody-Drug Conjugates), these drugs build a stronger treatment defense line for lung cancer patients of different subtypes and stages.
Precision Strikes:
ADC Drugs Usher in a New Era of Targeted Chemotherapy
ADC drugs (Antibody-Drug Conjugates), known as “biological missiles” for their precision and high efficacy, are profoundly changing the treatment landscape for lung cancer.
Sacituzumab Govitecan
As a novel TROP-2-targeting ADC, it has shown favorable efficacy in advanced lung cancer patients who have failed multiple lines of treatment, offering a new option for drug-resistant patients.
Trastuzumab Deruxtecan
Specifically targeting lung cancer patients with HER2 mutations or amplifications, it precisely delivers chemotherapy drugs to tumor cells, ushering in an efficient, low-toxicity targeted treatment regimen for this previously poor-prognosis subtype.
At Delta Hospital, this means that even for patients with complex conditions and progression after multiple lines of therapy, eligible patients still have the opportunity to access these internationally advanced ‘cancer-fighting weapons’.
Breaking Bottlenecks:
Novel Chemotherapy and Targeted Drugs Cover Diverse Patient Populations
From refractory small cell lung cancer to rare targets, Delta’s “arsenal” has been comprehensively upgraded.
Lurbinectedin
This novel chemotherapy drug brings new hope for breakthroughs in relapsed small cell lung cancer patients, rewriting treatment outcomes for this difficult-to-treat tumor type.
MET Inhibitors
Targeting rare targets such as MET exon 14 skipping mutations, Delta has equipped highly selective MET-TKI drugs, ensuring that “rare” no longer means “no treatment available.”
RET Inhibitors
For patients with RET fusion-positive lung cancer, Delta provides precise RET-TKI therapy, truly advancing lung cancer management into the era of “chronic disease” management.
Beyond the Drugs:
Systematic Diagnosis and Treatment Maximizes the Value of New Drugs
“Access to new drugs” is the first step; how to effectively use these “weapons” is the key. At the Oncology Department of Shanghai Delta Hospital, a comprehensive diagnosis and treatment system supports the maximization of the efficacy of cutting-edge drugs:
Precision Testing First
Before medication, precise pathology and genetic testing identify the patient’s driver genes and biomarkers, ensuring each new drug is used for the right patient.
Multidisciplinary Team (MDT) Support
The introduction of new drugs is never an isolated “prescription” but requires joint decision-making with experts from surgery, radiation oncology, radiology, and other disciplines. Delta’s mature MDT mechanism develops personalized, whole-course treatment plans incorporating new drug therapies for each patient.
Comprehensive Management Assurance
From in-hospital treatment to home recovery, an information system enables whole-course tracking and management, closely monitoring efficacy and adverse reactions, making treatment safer and more coherent.
At the Oncology Department of Shanghai Delta Hospital, cutting-edge is not out of reach, and innovation is not just on paper.
We are committed to enabling more patients to access high-quality diagnosis and treatment services that are synchronized with international standards, right at their doorstep. As a designated medical insurance institution, patients can conveniently use medical insurance for settlement at our hospital, effectively reducing the financial burden of seeking medical care.
Here, supported by a multidisciplinary expert team, we combine cutting-edge treatment concepts with the application of innovative drugs to tailor personalized diagnosis and treatment plans for patients. Through professional medical interventions, we build a scientific and comprehensive treatment pathway for every patient, delivering sustained confidence in treatment and hope for life.
On the journey against cancer,
Delta walks alongside you.